Mobilised peripheral blood stem cells are widely used for autografting in patients with chronic myeloid leukaemia (CML) and it is generally thought that a high proportion of Ph-negative progenitor cells in the graft is desirable. We report here the results of 91 stem cell mobilisations performed with various chemotherapy regimens followed by G-CSF. We show that mobilisation of Ph-negative cells is possible after diagnosis as well as in advanced stages of the disease. The yield of Ph-negative cells is highly dependent on the chemotherapy regimen: while the combination of idarubicin and cytarabin for 3-5 days (IC3-5) mobilised Ph-negative cells in most patients, high-dose cyclophosphamide was ineffective. Mobilisation of Ph-negative progenitor cells after IC3 was at least as effective as after IC5; however, less apheresis sessions were required, and toxicity was much reduced after IC3. Compared to historical controls, IC was equally effective as the widely used ICE/minilCE (idarubicin, cytarabin, etoposide) protocol. No correlation was found between graft quality and the cytogenetic response to subsequent treatment with interferon-␣. We conclude that IC3 is an effective and well-tolerated regimen for mobilising Ph-negative cells that compares well with more aggressive approaches such as IC5 and ICE/minilCE. Bone Marrow Transplantation (2001) 27, 1125-1132. Keywords: CML; autografting; stem cell mobilisation; mobilisation chemotherapy
restraints of age, concomitant medical conditions, and donor availability. In contrast to conventional chemotherapy, interferon-␣ prolongs survival, particularly in complete or major cytogenetic responders. 2 If the sustained cytogenetic responses seen in some patients are equivalent to biological cure of the disease is not yet clear.
More than 20 years after the first autologous stem cell transplantation (ASCT) for CML was performed, 3, 4 the role of autografting remains controversial since its effect on survival is unclear. In the majority of published studies, the survival data compared favourably with those of historical controls 5 but until now, no controlled trial has been carried out. Several studies in Europe are currently underway that might finally resolve the issue. In contrast to the lack of firm data concerning its clinical effectiveness, the rational base of ASCT for CML is well-founded. Ph-negative haemopoiesis is not infrequently established after intensive chemotherapy 6, 7 and it has become clear that (presumably normal) Ph-negative early progenitor cells co-exist with the Ph-positive clone in many CML patients, particularly in early stages of the disease. 8 These Ph-negative progenitor cells can be mobilised into the peripheral blood after intensive chemotherapy followed by G-CSF and are nowadays the preferred source of stem cells used for autografts. Current thinking holds that autografting may prolong survival by reducing the total burden of leukaemic stem cells that are capable of acquiring additional genetic lesions which finally lead to disease progression. Consequently, attempts were made to achieve a maximum degree of Ph negativity in the grafts in order to minimise the pool of leukaemic stem cells re-infused with the graft. Most of the available data indicate that mobilisation early after diagnosis produces grafts with a higher degree of Ph negativity. 9, 10 Furthermore, there is evidence that the chemotherapy regimen used for mobilisation may also influence the quality of the leukapheresis products. 9, 11 Between 1994 and 2000, 91 CML patients were mobilised within two clinical trials of the East German Study Group Haematology/Oncology (OSHO). The initial trial, designed as a pilot study, included 20 patients in late chronic phase. In the subsequent prospective study (CML 95 trial), 71 newly diagnosed patients underwent stem cell mobilisation. Mobilisation regimens were high-dose cyclo-phosphamide (HD-CY) and idarubicin/cytarabine (IC) for 3-5 days (IC3-IC5), followed by G-CSF. We show that IC regimens were able to mobilise substantial amounts of Phnegative progenitor cells in newly diagnosed as well as patients in late chronic phase, whereas HD-CY is not effective. Compared to the generally well-tolerated IC3 regimen, IC5 was associated with significantly more toxicity. Although more leukapheresis sessions were required after IC5 compared to IC3, the quality of the IC5-mobilised products in terms of numbers of CFU-GM was inferior. Moreover, the yield of Ph-negative progenitor cells after IC3 was at least as good as after IC5 suggesting that dose intensification does not necessarily result in better grafts for subsequent transplantation.
Patients and methods

Patients (Table 1)
For the pilot study, patients were eligible if they had Phpositive CML in chronic or accelerated phase defined by the IBMTR criteria (Provisional Form No. 089 LK), were Ͻ58 years of age and gave voluntary informed consent. The limit of 58 years at study entry was chosen because the risk of a potential subsequent autograft (Ͼ18 months from enty) was felt to be unacceptably high in patients above the age of 60. All patients had been treated with monotherapy or combinations of HU, IFN and/or cytarabine prior to mobilisation chemotherapy. Sokal risk was higher in the HD-CY group (6/7 patients with high or intermediate risk) compared to IC3-5 (4/11 patients altogether; P = 0.32). In two cases the Sokal risk was not recorded. The prospective study (CML 95) was designed to investigate the value of autografting in patients below the age of 58 without compatible sibling donor. After stem cell mobilisation these patients were randomised to receive either IFN-␣ plus hydroxyurea (HU) or IFN-␣ plus cytarabine. If no major cytogenetic response (Ͻ35% Ph-negative) occurred at any time within an 18 month observation period, the patients were offered an autograft. The study design is outlined in Table 1 Patient characteristics
Mobilisation regimen
Pilot study CML 95 prospective trial 2 ) were administered for 3, 4 and 5 days, respectively, followed by G-CSF (2 ϫ 5 g/kg s.c. day 6 to harvest). Supportive care followed institutional guidelines. As a rule, leukaphereses were started as soon as /l. In several cases, lower CD34 ϩ cell counts had to be accepted. Leukaphereses were continued until a minimum of 4 ϫ 10 6 CD34 ϩ cells/kg had been collected. If this could not be achieved despite repeated leukapheresis sessions, a minimum of 2 ϫ 10 6
CD34
ϩ cells/kg was accepted and scored as successful mobilisation. All procedures were carried out with a Cobe Specta cell separator (Gambro, Planegg, Germany).
FACS analysis
For frequency detection of CD34 ϩ cells, the cells in the apheresis products were labelled with an FITC-conjugated mAB (Becton Dickinson, Heidelberg, Germany) and analysed on a FACScan cell sorter (Becton Dickinson).
Cytogenetic analysis
Cytogenetic analysis was done on each individual stem cell apheresis product. In the beginning R-banding was used. 12 Whenever possible, 25 or more metaphases were analysed. Later during the study, hypermetaphase fluorescence in situ hybridisation (FISH) 13 was applied. In order to express the overall Ph status of a stem cell collection all analysable metaphases from the individual apheresis products were pooled together.
Clonogenic assays
Clonogenicity of the apheresis products was assessed in standard replicate methycellulose assays as described.
14 Day 14 CFU-GM colonies were scored under an inverted microscope.
Statistics
Comparisons between the different treatment regimens were performed with Fisher's exact test or 2 test for binary variables (eg Sokal risk, categorised cytogenetic response) and the Mann-Whitney test for continuous variables (eg duration of neutropenia or thrombocytopenia, recovery of WBC, or time of hospitalisation). A logistic-regression model was used to assess the joint effect of the pre-study variables on cytogenetic response after 18 months IFN-␣-based combination treatment. All statistical analyses were carried out with the SPSS software system.
Results
Haematopoietic recovery and treatment-related toxicity (Table 2)
In the pilot study, mobilisation with HD-CY was very well tolerated with limited toxicity. The median duration of neutropenia Ͻ0.5 ϫ 10 9 /1 (6 vs 16 days, P = 0.0074) and time to WBC Ͼ1 ϫ 10 9 /l (13 vs 24 days, P = 0.0014) as well as the duration of thrombocytopenia Ͻ20 ϫ 10 9 /1 (4 vs 13 days, P = 0.0054) was shorter compared to the largest group of IC-mobilised patients in the pilot study (IC4, n = 8). Not surprisingly, there was a trend towards more Bone Marrow Transplantation severe haematological toxicity, longer periods of i.v. antibiotics and longer hospitalisation with each additional day of IC. The numbers are, however, too small to allow for statistical analysis. No treatment-related deaths occurred with any of the regimens.
In the CML 95 prospective trial a total of 15 patients was mobilised with IC5. Although these patients were in early chronic phase, the regimen-related toxicities were severe and deemed unacceptable. Therefore, the intensity of chemotherapy was reduced to IC4 (only two patients, one of whom died from pneumonia) and then immediately to IC3. Compared to IC5, the IC3 regimen was generally well tolerated and resulted in significantly less toxicity. This holds true for neutropenia Ͻ0.5 ϫ 10 9 /l (median 15 days for IC5 vs 9 for IC3, P = 0.0007), median recovery of WBC Ͼ1 ϫ 10 9 /l (31 days vs 18, P Ͻ 0.00005) and thrombocytopenia Ͻ20 ϫ 10 9 /l (median 13 days vs 5, P = 0.001). As a consequence, median time of hospitalisation (22 days for IC3 vs 35 for IC5, P Ͻ 0.00005), median time on i.v. antibiotics (0 vs 16 days, P Ͻ 0.00005), and transfusion requirements (packed red cells, median 6 vs 12, P = 0.0028; platelets; median 5 vs 10, P = 0.0045) were all significantly lower in the IC3 regimen.
Leukapheresis products (Table 3, Table 4A and B)
Between 20 and 24 l of blood were processed per session. In the pilot study, mobilisation was successful in 17/20 patients and required a median of 2 (range 1-9) leukaphereses. There was no consistent difference in terms of nucleated cells, CD34
ϩ cells and CFU-GM mobilised with the various regimens. While mobilisation (ie at least 2 ϫ 10 6 /kg CD34 ϩ cells) was possible with all regimens, stem cell collections mobilised with cyclophosphamide were almost exclusively Ph-positive (median 91% Ph-positive, range 84-100%) while IC mobilisation resulted in enrichment for Ph-negative cells in all but two patients. In 8/11 of IC-mobilised patients, stem cell collections were in major cytogenetic remission with a mean of 10% (range 0-29%) Ph-positive metaphases. Based on these results, mobilisation with HD-CY was considered ineffective and thus not used in the subsequent prospective trial.
In the CML 95 prospective trial mobilisation with IC3 and IC5 was successful in 94.4% and 86.7% of patients, respectively, and required a median of two aphereses in IC3 and three in IC5. As in the pilot study, there was a trend toward lower numbers of nucleated cells in the IC3 than in the IC5 group (8.6 vs 11.6 ϫ 10 /kg, P = 0.007); moreover, only two apheresis sessions were required with IC3 compared to three with IC5 (P = 0.016).
Overall, 62% of IC5 and 86% of IC3 (P = 0.06) mobilised patients showed a major cytogenetic response in the graft (average of all leukapheresis products). In case of multiple aphereses there was no difference between the first and the last product in terms of cytogenetic response (data not shown). Table 4A and B detail the results in individual patients. 
Leucocytes at 1st apheresis (ϫ10 I C3 n a 2 n a 7 n a n a n a n a n a n a n a n a n a n a n a n a n a We also asked if graft parameters (Ph positivity, CD34 ϩ cells, CFU-GM) might be predictive of the subsequent response to IFN-␣ in the prospective study. However, no significant impact upon the cytogenetic response was demonstrable in univariate or multivariate analysis when patient characteristics (Sokal score, age), the median dose of IFN-␣ and median white blood count during IFN treatment and the combination (HU or cytarabine, respectively) were taken into account.
Bone Marrow Transplantation
Discussion
Although autografting for CML was introduced into clinical practice more than 15 years ago there is still no consensus as to its place in the overall management of the disease. The largest published series in the literature comprises 200 patients autografted in chronic phase (n = 142), accelerated phase (n = 30) or blast crisis (28) at eight different centres. 5 A recent update showed a 66% probability of survival at 4 years for patients autografted in chronic phase 15 which 9 who reported 59% major cytogenetic responses after mobilisation with 'IDAC' (idarubicin and cytarabine). 9 In this study, 8, 10 or 20 mg idarubicin/m 2 for 2 days were used together with 1 g/m 2 cytarabine for 5 days. Patients mobilised with the high dose of idarubicin achieved a higher rate of major cytogenetic responses than patients treated with the lower doses (77 vs 46%). In contrast, in our study IC3 proved to be at least as effective in producing major cytogenetic responses as IC5 (86 vs 62%), a difference that reached borderline significance (P = 0.06) in favour of IC3. This suggests that aggressive mobilisation does not necessarily mobilise more Ph-negative cells. The reason might be that the differential effect of IC3 becomes superseded by nonspecific toxicity at higher doses. In addition, IC3 was better tolerated than IC5, with much reduced morbidity and costs. Our results resemble a recently published comparison between 'ICE' (idarubicin and cytarabine as in IC3 plus 150 mg/m 2 etoposide for 5 days) and 'miniICE' (same regimen for 3 days) which showed equal efficacy but reduced toxicity for the miniICE regimen. 21 Interestingly, the rate of major cytogenetic responses is comparable in the IC3 and miniICE regimens (86 and 80%, respectively). However, more complete cytogenetic responses were seen with miniICE than with IC3 (53% vs 32%). A direct comparison between IC3 and miniICE would be required to assess the contribution of etoposide to the rate of cytogenetic responses. In contrast to previously published work, 22 we did not see more Ph-negative metaphases in the first compared to the last collection in the case of multiple leukaphereses. This may reflect the fact that most patients required only two aphereses, with a maximum of 24 h between them. Thus, there might not have been sufficient time to develop significant differences between the two sequential leukapheresis sessions. Thirteen patients were mobilised with IC in late chronic phase. Two mobilisations were not successful but in 8/11 successful mobilisations a complete or major cytogenetic response was seen. These data show that mobilisation of Ph-negative progenitor cells is feasible even in late chronic phase, in line with a recently published study which reported major or complete cytogenetic responses in 9/13 patients after mobilisation with miniICE or ICE. 23 In that study, mobilisation with cytarabine plus daunorubicin for 5 ϩ 2 or 7 ϩ 3 days, respectively, produced much inferior results: only 3/23 patients treated in this way achieved a major or complete cytogenetic response response. Thus, as with HD-CY, the right choice of mobilisation regimen proved be a major determinant of cytogenetic response. One potential concern with regard to the interpretation of our data is the relatively large number of mobilisations in which cytogenetics either failed (23.1%) or had to be based on less than 10 metaphases (7.7%). However, since these missing values occurred with comparable frequency in the various subgroups, they are unlikely to affect the results in any significant way.
Our study suggests that better cytogenetic responses may be achieved with a shorter and less toxic mobilisation regimen. This approach warrants further exploration: it is possBone Marrow Transplantation ible that the maximal differential of mobilisation occurs after even shorter courses of chemotherapy.
